Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.56USD
15 Dec 2017
Change (% chg)

$0.55 (+2.89%)
Prev Close
$19.01
Open
$19.10
Day's High
$19.80
Day's Low
$18.97
Volume
428,968
Avg. Vol
246,278
52-wk High
$27.07
52-wk Low
$8.73

Latest Key Developments (Source: Significant Developments)

Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients
Tuesday, 12 Dec 2017 07:00am EST 

Dec 12 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS.FDA APPROVED SNDA FOR OMIDRIA UNDER PRIORITY REVIEW.  Full Article

Omeros Corp reports Q3 loss per share $0.16
Thursday, 9 Nov 2017 04:02pm EST 

Nov 9 (Reuters) - Omeros Corp :Omeros Corporation reports third quarter 2017 financial results.Q3 loss per share $0.16.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Q3 revenue $21.7 million versus i/b/e/s view $17.9 million.Omeros Corp - ‍as of sept 30, 2017, co had $86.8 million of cash & cash equivalents available for operations & $5.8 million in restricted cash​.  Full Article

OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721
Thursday, 26 Oct 2017 11:30am EDT 

Oct 26 (Reuters) - Omeros Corp ::OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.‍OMS721 HAS BEEN WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN IDENTIFIED​.3 OF 4 PATIENTS FOR WHOM OMS721 TREATMENT WAS DISCONTINUED EARLY EXPERIENCED DETERIORATION OF THEIR CONDITIONS AND SUBSEQUENTLY DIED​.‍PREPARING TO INITIATE OMS721 PHASE 3 CLINICAL TRIAL, PURSUING FDA'S BREAKTHROUGH THERAPY DESIGNATION, EUROPEAN MEDICINES AGENCY'S PRIME STATUS​.  Full Article

Omeros Corp amends term loan agreement
Tuesday, 17 Oct 2017 09:02am EDT 

Oct 17 (Reuters) - Omeros Corp :On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​.Pursuant to amendment, co to access second, third tranches of debt financing under loan agreement for up to $25 million and $20 million.  Full Article

OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR
Thursday, 5 Oct 2017 11:00am EDT 

Oct 5 (Reuters) - Omeros Corp ::OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR.ENTERED INTO A SETTLEMENT AGREEMENT WITH PAR PHARMACEUTICAL, INC. AND ITS SUBSIDIARY RESOLVING OMEROS' PATENT LITIGATION AGAINST PAR​.UNDER SETTLEMENT, PAR TO PAY TO CO ROYALTY OF 15% OF PAR'S NET SALES OF ANY GENERIC VERSION OF OMIDRIA UNTIL LATEST EXPIRATION OF PATENTS.‍LAST-TO-EXPIRE OF OMEROS' ORANGE BOOK LISTED PATENTS FOR OMIDRIA EXPIRES ON OCTOBER 23, 2033​.UNLESS SUBSEQUENTLY AUTHORIZED IN SETTLEMENT AGREEMENT, PAR WILL BE PROHIBITED FROM LAUNCHING GENERIC VERSION OF OMIDRIA UNTIL APRIL 1, 2032.  Full Article

Omeros announces pricing of public offering of common stock
Tuesday, 15 Aug 2017 09:17am EDT 

Aug 15 (Reuters) - Omeros Corp :Omeros announces pricing of public offering of common stock.Says public offering of 3.00 million common shares priced at $22.75per share.  Full Article

Omeros announces public offering of common stock
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Omeros Corp -:Omeros announces public offering of common stock.Says offering 3.00 million common shares.  Full Article

Omeros Corporation Q2 loss per share $0.33
Tuesday, 8 Aug 2017 04:02pm EDT 

Aug 8 (Reuters) - Omeros Corp :Omeros corporation reports second quarter 2017 financial results.Q2 loss per share $0.33.Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Q2 revenue $17.2 million versus I/B/E/S view $14.4 million.  Full Article

FDA grants orphan drug designation to Omeros’ OMS721
Friday, 4 Aug 2017 11:10am EDT 

Aug 4 (Reuters) - Omeros Corp ::FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy.Says co plans to begin enrolling patients in its Phase 3 registration trial in IGA nephropathy later in 2017​.  Full Article

Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy
Tuesday, 13 Jun 2017 11:30am EDT 

June 13 (Reuters) - Omeros Corp ::FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy.Omeros' second phase 3 clinical program for OMS721 slated to begin this year.‍OMS721 is also being evaluated in a phase 3 clinical program for atypical hemolytic uremic syndrome​.‍OMS721 also being evaluated in a phase 2 clinical program for hematopoietic stem cell transplant-associated thrombotic microangiopathy​.One or more additional OMS721 phase 3 clinical programs planned to initiate this year in IgA nephropathy, stem cell transplant-associated TMA.Following discussions with FDA and European Medicines Agency, phase 3 program for OMS721 in atypical hemolytic uremic syndrome is in progress.Preparing to initiate manufacturing scale-up of its MASP-3 antibodies in advance of clinical trials.Omeros also expects to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection.Preliminary clinical evidence indicating that drug may demonstrate "substantial" improvement over existing therapies is required.  Full Article

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS